[144] Crinetics Pharmaceuticals, Inc. SEC Filing

CORINUS PHARMACEUTICALS insider sales reported via Form 144: the filing discloses open-market dispositions totaling 120,408 shares across four reported 10b5-1 transactions in March–April 2026.

Rhea-AI Filing Summary

CORINUS PHARMACEUTICALS insider sales reported via Form 144: the filing discloses open-market dispositions totaling 120,408 shares across four reported 10b5-1 transactions in March–April 2026. The filing also lists an exercise of 8,985 stock options on 05/04/2026 and 500 RSUs from 03/15/2025.

Key Figures

Total shares sold (reported): 120,408 shares Largest single sale: 85,163 shares Other sales (examples): 20,900 shares; 4,434 shares; 9,911 shares +2 more

5 metrics

Total shares sold (reported) 120,408 shares Aggregate of four 10b5-1 transactions dated Mar–Apr 2026

Largest single sale 85,163 shares Sale on 04/08/2026 for $3,414,701.10

Other sales (examples) 20,900 shares; 4,434 shares; 9,911 shares Sales on 04/14/2026, 04/13/2026, and 03/16/2026 with listed proceeds

Option exercise listed 8,985 shares Exercise of stock options recorded 05/04/2026

Restricted Stock Units recorded 500 RSUs Restricted Stock Units dated 03/15/2025

Key Terms

10b5-1, Form 144, Restricted Stock Units

3 terms

10b5-1 regulatory

"10b5-1 Sales for JEFF KNIGHT 6055 Lusk Boulevard San Diego"

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

Form 144 regulatory

"Filer Information | 144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Restricted Stock Units financial

"Restricted Stock Units | 03/15/2025 | Issuer | 500"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CRNX Form 144 disclose about insider sales?

It reports open-market sales totaling 120,408 shares across four 10b5-1 transactions. The entries list trades on 03/16/2026, 04/08/2026, 04/13/2026, and 04/14/2026 with stated proceeds.

Who executed the 10b5-1 sales reported in the filing?

The sales were executed by Jeff Knight under 10b5-1 plans. The filing lists his San Diego address and per-trade share counts and gross proceeds for each discrete sale reported in March–April 2026.

What option exercises or grants are noted in the Form 144?

The filing lists an exercise of 8,985 stock options on 05/04/2026 and 500 RSUs dated 03/15/2025. These items are disclosed alongside the resale transactions in the same submission.

How much cash was reported from the largest single sale?

The largest single reported sale was 85,163 shares on 04/08/2026 for $3,414,701.10. Other listed trades show their respective gross proceeds tied to each share count in the filing.

Does the Form 144 indicate proceeds go to the issuer or selling holder?

The listed 10b5-1 entries are sales by the reporting person (selling holder). The filing shows gross proceeds per transaction; it does not state proceeds are issued to the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/04/2026 - 04:26 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001881007
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Crinetics Pharmaceuticals, Inc.
SEC File Number	001-38583
Address of Issuer	6055 Lusk Boulevard San Diego CALIFORNIA 92121
Phone	8584506464
Name of Person for Whose Account the Securities are To Be Sold	JEFF KNIGHT
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	9485	370104.70	104705330	05/04/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/04/2026	Exercise of Stock Options	Issuer			8985	05/04/2026	Cash
Common	03/15/2025	Restricted Stock Units	Issuer			500	03/15/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for JEFF KNIGHT 6055 Lusk Boulevard San Diego CA 92121	Common	04/14/2026	20900	839061.85
10b5-1 Sales for JEFF KNIGHT 6055 Lusk Boulevard San Diego CA 92121	Common	04/13/2026	4434	177438.04
10b5-1 Sales for JEFF KNIGHT 6055 Lusk Boulevard San Diego CA 92121	Common	04/08/2026	85163	3414701.10
JEFF KNIGHT 6055 Lusk Boulevard San Diego CA 92121	Common	03/16/2026	9911	370411.47

144: Remarks and Signature

Remarks
Date of Notice	05/04/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/12/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jeff Knight
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)